InCarda Therapeutics, Inc., a San Francisco, CA-based biotechnology company focused on the development and commercialization of therapies for acute cardiovascular conditions via the inhalation route, raised over $5m Series A financing.
Potential additional tranches can bring to a total of $1.5m.
The round was led by Morningside Venture with participation from a consortium of physicians and other health care and high tech professionals. In conjunction with the funding, Reenie McCarthy, representing Morningside, will join InCarda’s board of directors.
The company intends to use the funds to further the company’s lead cardiovascular program for an inhaled therapy intended to treat paroxysmal atrial fibrillation (PAF).
Led by Grace E. Colon, Ph.D., chief executive officer and president, InCarda is advancing an inhaled therapy intended to treat paroxysmal atrial fibrillation (PAF) and is also working on additional research concepts that leverage the same platform technology to target the heart for acute cardiac conditions.